1. Data on file. Available from CSL Behring as DOF PVG-002.
  2. Immune Deficiency Foundation (IDF). About primary immunodeficiencies. Accessed September 15, 2017.
  3. Immune Deficiency Foundation (IDF). Specific diseases. Accessed September 15, 2017.
  4. Immune Deficiency Foundation (IDF). Immunoglobulin therapy and other medical therapies for antibody deficiencies. September 15, 2017.
  5. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11(6):532-538.
  6. Siegel J. IVIg medication safety: a stepwise guide to production selection and use. Pharm Pract News. Dec 2010.
  7. Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharm Pract News. Jan 2010.
  8. GBS/CIDP Foundation International. Recently diagnosed with CIDP." rel="external" class="interstitial" href=""> Accessed September 15, 2017.
  9. US Dept of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Chronic inflammatory demyelinating polyneuropathy (CIDP). Accessed September 15, 2017.
  10. US Dept of Health and Human Services. National Institute of Health. National Heart, Lung and Blood Institute. What is immune thrombocytopenia? Accessed September 15, 2017.
  11. Neunert C, Lim K, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;17(6):4190-4207.
  12. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236.
  13. US Dept of Health and Human Services. National Institutes of Health. National Health, Lung, and Blood Institute. How is immune thrombocytopenia (ITP) treated? Accessed September 15, 2017.
  14. National Institutes of Health: Safety and efficacy of intravenous immunoglobulin IgPro10 in patients with primary immunodeficiencies. Accessed September 15, 2017.
  15. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137-144.
  16. Cramer M, Frei R, Sebald A, Maeder M. Stability over 36 months of new liquid 10% polyclonial immunoglobulin product (IgPro10. Privigen®) stabilized with L-proline. Vox Sang. 2009;96(3):219-225.
  17. Bolli R, Woodtli K, Bärtschi M, Höfferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biological. 2010;38(1):150-157.
  18. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5)734-745.
  19. Sun A, Teschner W, Yel L. Improving patient tolerability in immunoglobulin treatment: focus on stabilizer effects. Expert Rev Clin Immunol. 2013;9(6):577-587.
  20. Simon HU, Späth PJ. IVIG mechanisms of action. Allergy. 2003;58(7):543-552.
  21. Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous polyclonal immunoglobulin in autoimmune diseases: clinical indications and mechanisms of action. Drug Discov Today Ther Strateg Autoimmun. 2009;6(1):5-11.
  22. Jacob S, Rajabally Y. Current proposed mechanism of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337-342.
  23. Imbach P, Lazarus AH, Kühne T. Intravenous immunoglobulin induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sang. 2009;98(3):385-394.
  24. US Department of Health & Human Services, Center for Medicare & Medicaid Services. International Classification of Diseases, Tenth Revision, Clinical Modifications (ICD-10-CM). 2018 Codes Tables and Index. Accessed September 15, 2017.
  25. American Medical Association. Medicine/hydration, therapeutic, prophylactic, diagnostic injections and infusions, and chemotherapy. In: American Medical Association, ed. CPT 2016. Chicago, IL: American Medical Association; 2016:650-651.
  26. US Department of Health and Human Services, Center for Medicare & Medicaid Services. HCPCS Release & Code Sets. Accessed September 15, 2017.
  27. HIPAA Space Healthcare Procedure Coding System Codes Lookup S9338. Accessed September 15, 2017.
  28. Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007; 27(5):497-502.
  29. Data on file. Available from CSL Behring as DOF PVG-003.
You are now leaving the current website.

Do you want to continue?

Welcome to

Help us find the right content for you.